Skip To Main Content
Diying Shen on Muck Rack

Diying Shen

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Diying

Contact Diying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

|
By Qingyuan Xu, Linya Wang, Ning Liao, Mincui Zheng, Yunpeng Dai, Shaoyan Hu, Li Wang, Qun Hu, Xin Tian, Xiaohuan Wang, Yuanyuan Zhang, Pengli Huang, Ying Choon Wu, Wei Lin, Jia Fan, Ruidong Zhang, Yaguang Peng, Huyong Zheng, Diying Shen, Jiaole Yu, Peijing Qi
| Nature Verified
In recent years, the targeted therapy combining arsenic with all-trans retinoic acid (ATRA) has dramatically improved outcomes in pediatric acute promyelocytic leukemia (APL) [1, 2]. However, 5–10% of patients still experience relapse [3], which remains a major barrier to cure. Within this modern therapeutic framework, the risk factors for relapse in pediatric APL—particularly the role of arsenic pharmacokinetics—are not fully defined.
Open in Who Shared Issue with article?
See all 1 articles